A. N. Prior’s writings should obviously be studied already for historical reasons. His inventions of modern temporal logic and hybrid logic are clearly important events in the history of logic. But the enduring importance of studying his works also rests on his methodological approach, which remains highly relevant also for systematical reasons. In this paper we argue that Prior’s formulation in the 1950s of a tense-logical paradigm for the study of time should be understood in the light of at least (...) three other principles or perspectives which were manifest already in his studies during the 1940s and further developed in the 1950s: his emphasis on the value of interdisciplinary studies, his reflections on formalisation and his view of the role of symbolic logic in conceptual studies and in the philosophy of science. Our investigation into Prior’s basic tenets and principles makes extensive use of Prior’s Nachlass. It is thereby also exemplified how his correspondence and unpublished papers contain important information for a deeper understanding of Prior’s paradigm for the study of time. (shrink)

Temporal Logic: From Ancient Ideas to Artificial Intelligence deals with the history of temporal logic as well as the crucial systematic questions within the field. The book studies the rich contributions from ancient and medieval philosophy up to the downfall of temporal logic in the Renaissance. The modern rediscovery of the subject, which is especially due to the work of A. N. Prior, is described, leading into a thorough discussion of the use of temporal logic in computer science and the (...) understanding of natural language. Temporal Logic: From Ancient Ideas to Artificial Intelligence thus interweaves linguistic, philosophical and computational aspects into an informative and inspiring whole. (shrink)

Background: Thrombolytic drugs to treat an acute ischaemic stroke reduce the risk of death or major disability. The treatment is, however, also associated with an increased risk of potentially fatal intracranial bleeding. This confronts the patient with the dilemma of whether or not to take a risk of a serious side effect in order to increase the likelihood of a favourable outcome. Objective: To explore acute stroke patients’ perception of risk and willingness to accept risks associated with thrombolytic drug treatment. (...) Design: Eleven patients who had been informed about thrombolytic drug treatment and had been through the process of deciding whether or not to participate in a thrombolytic drug trial went through repeated qualitative, semistructured interviews. Results: Many patients showed a limited perception of the risks connected with thrombolytic drug treatment. Some perceived the risk as not relevant to them and were reluctant to accept that treatment could cause harm. Others seemed to be aware that treatment would mean exposure to risk. The patients’ willingness to take a risk also varied substantially. Several statements revealed ambiguity and confusion about being involved in a decision about treatment. The patients’ reasoning about risk was put into the context of their health-related experiences and life histories. Several patients wanted the doctor to be responsible for the decisions. Conclusion: Acute stroke patients’ difficulties in perceiving and processing information about risk may reduce their ability to be involved in clinical decisions where risks are involved. (shrink)